Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test

Digestive Diseases and Sciences

Volumn 50, Issue 7, 2005, Pages 1207-1213

  Giannini, Edoardo G ^a   Malfatti, Federica ^a   Botta, Federica ^a   Polegato, Simone ^a   Testa, Emanuela ^a   Fumagalli, Alessandra ^a   Mamone, Mario ^a   Savarino, Vincenzo ^a   Testa, Roberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

13C aminopyrine breath test; Clarithromycin; Helicobacter pylori; Liver function; Metronidazole; Rabeprazole

Indexed keywords

AMINOPHENAZONE C 13; CLARITHROMYCIN; CYTOCHROME P450; METRONIDAZOLE; RABEPRAZOLE; UNCLASSIFIED DRUG; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; AMINOPHENAZONE; ANTIINFECTIVE AGENT; BENZIMIDAZOLE DERIVATIVE; CARBON; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; OMEPRAZOLE;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL PRACTICE; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER PYLORI; HUMAN; LIVER FUNCTION; MALE; PATIENT; PRIORITY JOURNAL; CLINICAL TRIAL; DRUG COMBINATION; DRUG INTERACTION; ENZYMOLOGY; HELICOBACTER INFECTION; LIVER; LIVER FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; AMINOPYRINE; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BENZIMIDAZOLES; BREATH TESTS; CARBON ISOTOPES; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE;

EID: 23044463770     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2761-z     Document Type: Article

References (42)

1. Pounder RE, Ng D: The prevalence of Helicobacter pylori in different countries. Aliment Pharmacol Ther 9 (Suppl. 2):33-39, 1995
2. Tytgat GN: Helicobacter pylori: Where are we and where are we going? Aliment Pharmacol Ther 14 (Suppl 3):55-58, 2000
3. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G; The European Helicobacter Pylori Study Group (EHPSG): Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16:167-180, 2002
4. Edwards SJ, Lind T, Lundell L: Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 15:1729-1736, 2001
5. Tutuian R, Katz PO, Castell DO: A PPI is a PPI is a PPI; lessons from prolonged intragastric pH monitoring. Gastroenterology 118 (Suppl 2): A17, 2000 (abstract)
6. McColl KEL, Kennerley P: Proton pump inhibitors - Differences emerge in hepatic metabolism. Digest Liver Dis 34:461-467, 2002
7. Ishizaki T, Horia Y: Review article: Cytochrome P450 and the metabolism of proton pump inhibitors - Emphasis on rabeprazole. Aliment Pharmacol Pharmacol 13 (Suppl 3):27-36, 1999
8. Pilotto A, Salles N: Helicobacter pylori infection in geriatrics. Helicobacter 7 (Suppl 1):56-62, 2002
9. Whitaker M: Proton pump inhibitors in the elderly. Eur J Gastroenterol Hepatol 14 (Suppl 1):S5-S9, 2002
10. Atkin PA, Veitch PC, Veitch EM, Ogle SJ: The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging 14:141-152, 1999
11. Herrlinger C, Klotz U: Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 15:897-918, 2001
12. Calvet X, Navarro M, Gil M, Lafont A, Sanfeliu I, Brullet E, Campo R, Dalmau B, Rivero E, Mas P: Epidemiology of peptic ulcer disease in cirrhotic patients: role of Helicobacter pylori infection. Am J Gastroenterol 93:2501-2507, 1998
13. 14C]omeprazole in patients with liver cirrhosis. Clin Pharmacokinet 24:71-78, 1993
14. Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M: Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 45:367-371, 1993
15. Huber R, Hartmann M, Bliesath H, Luhmann R, Steinijans VW, Zech K: Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 34 (Suppl 1):S7-S16, 1996
16. Hoyumpa AM, Trevino-Alnis H, Grimes I, Humpries TJ: Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Clin Ther 21:691-701, 1999
17. Sjovall H, Bjornsson E, Holmberg J, Hasselgren G, Rohss K, Hassan-Alin M: Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Eur J Gastroenterol Hepatol 14:491-496, 2002
18. Humpries TJ, Merritt GJ: Review article: Drug interactions with agents used to treat acid-related disease. Aliment Pharmacol Ther 13 (Suppl 3):18-26, 1999
19. Klotz U: Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 38:243-270, 2000
20. Giannini E, Romagnoli P, Fasoli A, Chiarbonello B, Malfatti F, Botta F, Risso D, Lantieri PB, Savarino V, Testa R: Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens. Am J Gastroenterol 95:2762-2767, 2000
21. Armuzzi A, Candelli M, Zocco MA, Andreoli A, De Lorenzo A, Nista EC, Miele L, Cremonini F, Cazzato IA, Grieco A, Gasbarrini G, Gasbarrini A: Breath testing for human liver function assessment. Aliment Pharmacol Ther 16:1977-1996, 2002
22. 13C-Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 16:717-725, 2002
23. 13C]Aminopyrine breath test detects altered liver metabolism caused by low-dose oral contraceptives. Dig Dis Sci 40:2417-2422, 1995
24. 13C] aminopyrine breath test. Dig Dis Sci 46:133-139, 2001
25. 2-Breath Tests at the Laboratory "Digestion-Absorption. Leuven, Belgium, University Hospital Gasthuisberg Leuven, 1996, pp 43-54
26. Haycock G, Shwartz G, Wisotsky D: Geometric method for measuring body surface area. J Pediatr 93:62-66, 1978
27. 13C-urea breath test. Am J Gastroenterol 94:1203-1208, 1999
28. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 55:843-852, 2000
29. Wen X, Wang JS, Backman JT, Kivisto KT, Neuvonen PJ: Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 29:1359-1361, 2001
30. Kariya S, Isozaki S, Uchino K, Suzuki T, Narimatsu S: Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull 19:1511-1514, 1996
31. Rodvold KA: Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 37:385-398, 1999
32. Ushiama H, Echizen H, Nachi S, Ohnishi A: Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther 72:33-43, 2002
33. Haas CE, Kaufman DC, DiCenzo RC: Effects of metronidazole on hepatic CYP3A4 activity. Pharmacotherapy 21:1192-1195, 2001
34. Lew EA: Review article: Pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther 13 (Suppl 5):11-16, 1999
35. Carswell CI, Goa KL: Rabeprazole. An update of its use in acid-related disorders. Drugs 61:2327-2356, 2001
36. Gerson LB, Triadafilopoulos G: Proton pump inhibitors and their drug interactions: and evidence-based approach. Eur J Gastroenterol Hepatol 13:611-616, 2001
37. Homma M, Itagaki F, Yuzawa K, Fukao K, Kohda Y: Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation 73:303-304, 2002
38. Chiloiro M, Russo F, Riezzo G, Leoci C, Clemente C, Messa C, Di Leo A: Effect of Helicobacter pylori infection on gastric emptying and gastrointestinal hormones in dyspeptic and healthy subjects. Dig Dis Sci 46:46-53, 2001
39. Koskenpato J, Korppi-Tommola T, Kairemo K, Farkkila M: Long-term follow-up study of gastric emptying and Helicobacter pylori eradication among patients with functional dyspepsia. Dig Dis Sci 45:1763-1768, 2000
40. Fukuda Y, Bamba H, Okui M, Tamura K, Tanida N, Satomi M, Shimoyama T, Nishigami T: Helicobacter pylori infection increases mucosal permeability of the stomach and intestine. Digestion 63 (Suppl 1):93-96, 2001
41. Giannini E, Fasoli A, Borro P, Chiarbonello B, Malfatti F, Romagnoli P, Botta F, Testa E, Fumagalli A, Polegato S, Savarino V, Testa R: Impairment of cytochrome P-450 dependent liver activity in cirrhotic patients with Helicobacter pylori infection. Aliment Pharmacol Ther 15:1975-1982, 2001
42. Giannini E, Fasoli A, Botta F, Romagnoli P, Malfatti F, Chiarbonello B, Mamone M, Savarino V, Testa R: Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. Dig Dis Sci 48:802-808, 2003